Bank of New York Mellon’s Cytek Biosciences CTKB Stock Holding History

Bank of New York Mellon’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.65M	Sell	371,427 -237,220	-39%	-$1.01M	﹤0.01%	3066
2026 Q1	$2.66M	Sell	608,647 -29,282	-5%	-$138K	﹤0.01%	2669
2025 Q4	$3.22M	Sell	637,929 -35,640	-5%	-$165K	﹤0.01%	2578
2025 Q3	$2.34M	Sell	673,569 -26,344	-4%	-$98.9K	﹤0.01%	2719
2025 Q2	$2.38M	Buy	699,913 +7,511	+1%	+$25K	﹤0.01%	2656
2025 Q1	$2.78M	Sell	692,402 -38,307	-5%	-$199K	﹤0.01%	2521
2024 Q4	$4.74M	Buy	730,709 +11,665	+2%	+$69.5K	﹤0.01%	2325
2024 Q3	$3.98M	Sell	719,044 -85,217	-11%	-$483K	﹤0.01%	2405
2024 Q2	$4.49M	Buy	804,261 +29,579	+4%	+$178K	﹤0.01%	2387
2024 Q1	$5.2M	Sell	774,682 -43,588	-5%	-$345K	﹤0.01%	2312
2023 Q4	$7.46M	Sell	818,270 -7,310	-0.9%	-$46K	﹤0.01%	2158
2023 Q3	$4.56M	Buy	825,580 +65,551	+9%	+$526K	﹤0.01%	2362
2023 Q2	$6.49M	Buy	760,029 +369,488	+95%	+$3.31M	﹤0.01%	2178
2023 Q1	$3.59M	Sell	390,541 -6,495	-2%	-$69.9K	﹤0.01%	2479
2022 Q4	$4.05M	Buy	397,036 +3,002	+0.8%	+$40.3K	﹤0.01%	2456
2022 Q3	$5.8M	Buy	394,034 +66,045	+20%	+$858K	﹤0.01%	2218
2022 Q2	$3.52M	Buy	327,989 +61,654	+23%	+$614K	﹤0.01%	2510
2022 Q1	$2.87M	Buy	266,335 +213,476	+404%	+$2.88M	﹤0.01%	2730
2021 Q4	$863K	Buy	52,859 +14,290	+37%	+$299K	﹤0.01%	3469
2021 Q3	$826K	Buy	+38,569	New	+$907K	﹤0.01%	3509

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Bank of New York Mellon's CTKB Position: Q2 2026 in Review

Bank of New York Mellon reduced its Cytek Biosciences (CTKB) stake by 39% in Q2 2026, selling an estimated $1.01M and leaving 371,427 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #3066.

Bank of New York Mellon first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $7.46M in Q4 2023. 48 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Bank of New York Mellon held 371,427 shares of Cytek Biosciences worth $1.65M as of Q2 2026.
Bank of New York Mellon sold 237,220 Cytek Biosciences shares in Q2 2026, an estimated $1.01M.
Cytek Biosciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3066 holding.
Bank of New York Mellon first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
Bank of New York Mellon's Cytek Biosciences position peaked at $7.46M in Q4 2023.
48 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.